Osterweis Capital Management Inc. Invests $15.14 Million in Repligen Corporation $RGEN

Osterweis Capital Management Inc. bought a new position in shares of Repligen Corporation (NASDAQ:RGEN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 110,995 shares of the biotechnology company’s stock, valued at approximately $15,144,000. Osterweis Capital Management Inc. owned approximately 0.20% of Repligen at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of RGEN. Measured Wealth Private Client Group LLC purchased a new stake in Repligen during the 3rd quarter worth about $29,000. Rachor Investment Advisory Services LLC purchased a new position in shares of Repligen in the 4th quarter valued at about $33,000. Los Angeles Capital Management LLC purchased a new position in shares of Repligen in the 4th quarter valued at about $36,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Repligen during the 2nd quarter worth about $52,000. Finally, Farther Finance Advisors LLC raised its position in shares of Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 128 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. The trade was a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.60% of the company’s stock.

Repligen Stock Up 0.3%

Shares of NASDAQ RGEN opened at $181.62 on Tuesday. The stock has a market cap of $10.25 billion, a PE ratio of 248.79, a price-to-earnings-growth ratio of 3.31 and a beta of 1.03. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $188.73. The business has a 50-day moving average price of $148.17 and a 200 day moving average price of $131.97.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The company had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same quarter in the previous year, the company posted $0.26 earnings per share. The firm’s revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities research analysts forecast that Repligen Corporation will post 2.06 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on RGEN shares. Evercore reaffirmed an “outperform” rating and issued a $160.00 price target on shares of Repligen in a report on Monday, July 6th. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Wells Fargo & Company boosted their price objective on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Benchmark upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a report on Tuesday, July 7th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $166.43.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.